Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 701-708

  Duprez, Daniel ^a   Ferdinand, Keith ^b   Purkayastha, Das ^c   Samuel, Rita ^c   Wright, Richard ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Atlanta Clinical Research Centers   (Georgia)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Pacific Heart Institute   (United States)

Author keywords

Ambulatory blood pressure; Ambulatory blood pressure monitoring; Amlodipine; Antihypertensive drugs; Combination therapy; Hydrochlorothiazide; Losartan; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; HYDROCHLOROTHIAZIDE; LOSARTAN; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 84863600240     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S25743     Document Type: Article

References (23)

1. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26:1290-1299.
2. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407-2415.
3. Pickering TG, White WB, Giles TD, et al. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4(2):56-61.
4. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156-161.
5. Falqui V, Viazzi F, Leoncini G, et al. Blood pressure load, vascular permeability and target organ damage in primary hypertension. J Nephrol. 2007;20 Suppl 12:S63-S67.
6. Bauwens F, Duprez D, De Buyzere M, Clement DL. Blood pressure load determines left ventricular mass in essential hypertension. Int J Cardiol. 1992;34(3):335-338.
7. White WB. How well does ambulatory blood pressure predict targetorgan disease and clinical outcome in patients with hypertension? Blood Press Monit. 1999;4 Suppl 2:S17-S21.
8. Hermida RC, Ayala DE, Smolensky MH, Portaluppi F. Chronotherapy in hypertensive patients: administration-time dependent effects of treatment on blood pressure regulation. Expert Rev Cardiovasc Ther. 2007; 5(3):463-475.
9. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008;13(2):123-129.
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-1252.
11. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50.
12. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16(2): 80-86.
13. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
14. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3): 290-300.
15. Wright RF, Duprez D, Purkayastha D, Samuel R, Ferdinand KC. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the EXforge as compared to Losartan Treatment in Stage 2 systolic hypertension (EXALT) study. J Clin Hypertens (Greenwich). 2011;13(8):588-597.
16. Maintenance and Support Services Organization (MSSO). Medical Dictionary for Regulatory Activities. Chantilly, VA: MSSO; 2011 [updated October 27]. Available from: http://www.meddramsso.com/. Accessed October 31, 2011.
17. Lefebvre J, Poirier L, Lacourciere Y. Methodology to determine duration of action for antihypertensive drugs. Ann Pharmacother. 2002;36(5): 874-881.
18. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe trial investigators. JAMA. 1999;282(6):539-546.
19. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension. 1994;24(6):793-801.
20. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38(4):852-857.
21. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20(11): 2183-2189.
22. Lacourcière Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25(10):615-622.
23. Izzo J, Melino M, Fernandez V, Lee J, Heyrman R. Twenty-four hour efficacy and safety of full-dose, triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide. J Clin Hypertens (Greenwich). 2010;12(Suppl 1):A34-A35.